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Effects of new generation triptans – frovatriptan and almotriptan 
– on hemodynamic parameters in intact male and female rats
The introduction of the second generation triptans in 
clinical and experimental practice was a major progress 
in the pharmacotherapy of migraine. Frovatriptan is a 
second generation triptan with strong 5-HT1B/1D seroto-
nergic agonism and low 5-HT1A/7 receptor affinity, while 
almotriptan possesses not only the typical 5-HT1B/1D re-
ceptor agonist activity, but shows an affinity to the 5-HT1F 
receptor. The aim of our study was to assess the impact of 
frovatriptan and almotriptan on hemodynamics in male 
and female rats. We used a non-invasive “tail-cuff” method 
to measure the arterial blood pressure. Female and male 
Wistar rats were treated separately with high and low 
dosages of frovatriptan and almotriptan. Male and female 
rats showed reduction in all hemodynamic parameters, 
but only male rats showed an increase in the heart rate. In 
general, we could say that both almotriptan and frovat-
riptan potentiate cardiovascular safety.
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Despite the fact that triptans were designed to exert relatively similar antimigraine 
activity and side-effects profile, there are some studies that show some controversies in 
their cardiovascular safety and sustainability. Several studies have shown that hyperten-
sion is often associated with migraine and can even lead to its chronic development. 
Hypertension is thought to aggravate vascular endothelial dysfunction, which negatively 
affects the incidence and severity of migraine attacks (1). The control of arterial pressure is 
closely related to the specificities of blood supply in some vascular areas. Neuronal brain 
activity is a major factor that could influence blood flow (2).
Serotonin (5-HT) could influence some heart functions by its receptors, the effects of 
which are very complex in essence. For example, 5-HT can act as a sympatholytic by activa-
tion of the 5-HT1 receptors on sympathetic nerve terminals that inhibit the norepinephrine 
(NE) release. This mechanism contributes to a reduced cardiac output, which is associated 
with a decrease in blood pressure. On the other side, 5-HT could have some stimulating 
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For example, the activation of 5-HT2A receptors in rats, 5-HT4 receptors in pigs and hu-
mans, and 5-HT7 receptors in cats leads to an increase of the heart rate. The authors assume 
that 5-HT could both increase and decrease blood pressure by its activity in the heart (4).
The frequency of triptan-related cardiovascular side-effects in clinical trials and in 
practice has been extremely low. When present, they usually affect patients with cardio-
vascular risk or cardiovascular disease. Few cases of cardiovascular side-effects were ob-
served among patients that do not suffer from any cardiovascular pathology. Side-effects 
include peripheral vasoconstriction and rise in blood pressure in the case of uncontrolled 
hypertension. Because of this, there is a need for careful triptan prescribing to patients at 
risk (5). Nowadays, there are no specific scales that could assess the efficacy of triptan treat-
ment during a migraine attack in patients suffering from hypertension.
Tullo et al. (6) made a retrospective analysis of three randomized, double-blind, cross-
over studies involving hypertensive and normotensive men and women aged 18–65 years 
suffering from migraine, with or without aura. The patients were treated with frovatriptan 
and other triptan agents (zolmitriptan, rizatriptan and almotriptan). Recurrent headaches 
have been more frequent among hypertonic patients than in normotensive patients treated 
with other triptans except frovatriptan, which is not surprising, having in mind the long 
half-life of the drug (~26 h). A conclusion that could be drawn from this is that hyperten-
sive patients are less susceptible to triptan treatment.
In the following research, we will make a comparative analysis of efficacy after one 
single application of frovatriptan and almotriptan on blood pressure and heart rate in male 
and female rats. We use single applications of these drugs because they are used only in 
the treatment of acute exacerbations and not as basic antimigraine therapy.
EXPERIMENTAL
Chemicals
Saline 0.9 % NaCl was used in control groups. Frovatriptan succinate monohydrate 
(frova) (≥ 98 %) and almotriptan malate (almo) (≥ 98 %) were obtained from Sigma-Aldrich 
Chemie GmbH (Germany).
Animals
Animals used in the experiments were male and female albino Wistar rats with an 
approximate body mass of 180–220 g. The total number of animals used in the experiments 
is 32 (16 males, 16 females), each group consisting of 8 animals. Female animals were of 
reproductive age, not ovariectomized and not estrogen-treated. All experimental rats were 
housed on a 12-hour light/dark cycle under controlled temperature and lighting condi-
tions, while food and water were provided ad libitum.
Exclusion criteria: underweight rats, diseased animals, not-matured enough animals, and 
animals that had been previously treated with other than the before-mentioned substances.
We have not registered any incidents during the experiments.
Experimental design
There were two series of experiments carried out on rats, based on sex: in the 1st series 
we had used female rats and in the 2nd series we had used male rats. For each experiment 
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in the 1st and in the 2nd series, there was one control group treated subcutaneously (s.c.) 
with saline 0.9 % NaCl only (0.1 mL per 100 g b.m.) and four test groups treated subcutane-
ously (s.c.) as it follows: the 1st group was injected with frovatriptan 2.5 mg kg–1 b.m.; the 
2nd group was injected with frovatriptan 5 mg kg–1 b.m.; the 3rd group was injected with 
almotriptan 3 mg kg–1 b.m.; the 4th group was injected with almotriptan 6 mg kg–1 b.m. 
Forty minutes after the drugs had been injected, animals were tested according to the in-
dicated method. All test groups in the respective series were compared to the control 
group (injected with saline only). The total number of animals used in the experiment was 
80: 40 males and 40 females;  8 animals in each group.
Method
The arterial blood pressure was examined non-invasively using the so-called “tail- 
-cuff” method. All the experiments were carried out by the hemodynamic apparatus NIBP 
200A (Biopac Systems Inc., USA) and its respective software package МР150. The animals 
were not anesthetized. All rats were initially warmed in a thermostat (Binder, Germany) 
up to 37 ° С. Afterwards, the animals were put into a restrainer in order to measure the 
arterial blood pressure using a cuff on the base of their tails. Before each measurement of 
the blood pressure, the rats were put into the restrainer for 5 min in order to get used to 
the stress levels. The values of systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) were calculated as the means of 3 independent measurements. Their derivatives – 
pulse pressure (PP) and mean arterial pressure (MAP) – were calculated as follows: PP = 
SBP – DBP and MAP = DBP + (PP/3).
All the experimental protocols in this study were approved by the Ethical Committee 
of the Bulgarian Food Safety Agency with № 97/22.05.14 and were carried out following 
the guidelines of the European Directive 2010/63/EU.
Statistical processing
The statistical software SPSS version 19.0 was used for the multi-variant analysis. The 
mean and standard error of the mean (± SEM) were calculated for each group. A non-
parametric Shapiro-Wilk test was performed to determine the level of distribution. F-test 
for variances and independent sample t-test, assuming equal or unequal variances, were 
used to compare the experimental groups with the corresponding control group. A p < 0.05 
was considered as representing a statistically significant difference.
RESULTS AND DISCUSSION
Cardiovascular effects of frovatriptan and almotriptan in female rats
In the first series of experiments, the female group of rats treated with frovatriptan of 
2.5 mg kg–1 did not exhibit any significant change in hemodynamic parameters. The only 
group of animals, that significantly reduced DBP and MAP compared to the control group 
with saline, were those injected with the higher dosage of frovatriptan 5 mg kg–1 (Fig. 1).
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Fig. 1. Cardiovascular effects of frovatriptan after single administration in female rats (mean ± SEM, 
n = 8). A significant difference compared to the control group: *p  < 0.05; DBP – diastolic blood pres-
sure, PP – pulse pressure, MAP – mean arterial pressure, SBP – systolic blood pressure.
Fig. 2. Cardiovascular effects of almotriptan after single administration in female rats (mean ± SEM, 
n = 8). A significant difference compared to the control group: *p  < 0.05; DBP – diastolic blood pres-
sure, PP – pulse pressure, MAP – mean arterial pressure, SBP – systolic blood pressure.
Fig. 2 shows that female groups treated with almotriptan in both dosages (3 and 6 
mg kg–1) showed significantly (p < 0.05) reduced SBP, DBP and MAP.
Heart rate was not influenced significantly in any female rat group treated with trip-
tan (Fig. 3).
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Cardiovascular effects of frovatriptan and almotriptan in male rats
The second series of experiments were conducted on intact male rats. The treated with 
frovatriptan at dosages of 2.5 and 5 mg kg–1 showed a significant (p < 0.05) decrease in each 
blood pressure value (SBP, DBP, PP, MAP) compared to the control group after a single 
subcutaneous application (Fig. 4).
For the male rats treated with almotriptan at dosages of 3 and 6 mg kg–1, a significant 
reduction (p < 0.05) of the three blood pressure values (SBP, DBP, MAP) was recorded com-
pared to the control group. There were no significant changes for the PP (Fig. 5).
Fig. 3. Effects of frovatriptan and almotriptan on the heart rate after single administration in female 
rats (mean ± SEM, n = 8).
Fig. 4. Cardiovascular effects of frovatriptan after single administration in male rats (mean ± SEM, n 
= 8). A significant difference compared to the control group: *p < 0.05; DBP – diastolic blood pressure, 
PP – pulse pressure, MAP – mean arterial pressure, SBP – systolic blood pressure.
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The heart rate was significantly increased in all groups of male rats treated with both 
triptans compared to the controls (Fig. 6).
Discussion of the results
In the experiments on intact male and female rats, both dosages of almotriptan de-
creased SBP, DBP and MAP, whereas frovatriptan did not show similar results in both 
sexes. Heart rate was not affected by any of the triptans tested on intact female rats. Almo-
triptan and frovatriptan generally showed hypotensive effects in both male and female 
rats. Keeping in mind that these drugs are serotonergic agonists, it should be mentioned 
that the effects of serotonin on the cardiovascular system are very complex and sophisti-
Fig. 5. Cardiovascular effects of almotriptan after single administration in male rats (mean ± SEM, n 
= 8). A significant difference compared to the control group: *p < 0.05; DBP – diastolic blood pressure, 
PP – pulse pressure, MAP – mean arterial pressure, SBP – systolic blood pressure.
Fig. 6. Effects of frovatriptan and almotriptan on the heart rate after single administration in male 
rats. (mean ± SEM, n = 8). A significant difference compared to the control group: *p < 0.05.
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cated. These may result either in bradycardia or tachycardia, hypotension or hypertension, 
vasoconstriction or vasodilatation, and all these effects are primarily mediated by 5-HT1, 
5-HT2 and 5-HT3 receptors (3).
Watts and Davis (7) reported that 5-HT1B/1D receptors are actively involved in cardio-
vascular effects and alter the physiological parameters of blood pressure and heart rate. In 
their review, they emphasize the role of 5-HT in reducing systemic blood pressure after 
single or multiple administrations of serotonin in rats. This effect is mainly due to interac-
tion with 5-HT1B/1D receptors. The activation of these receptors results also in decreased 
release of norepinephrine (NE) from noradrenergic neurons thus leading to a reduction in 
the contractile tone without resulting in vasodilation, which leads to hypotension (7). This 
effect is a possible explanation for the results in our experiments with almotriptan and 
frovatriptan on intact animals. Reboredo et al. (8) suggest that 5-HT1B/1D receptors are ex-
tremely expressed in mesenteric arteries and can mediate strong vasoconstriction effects (8).
In other studies, zolmitriptan is suggested to provoke a short-term increase in the 
arterial blood pressure (3). This effect is due to the contraction of the cranial blood vessels. 
Alternatively, vessels in the periphery and mainly in the vascular mesenteric vessels are 
also involved in this process. The acute parenteral administration of zolmitriptan and its 
short-term hypertension could be followed by long-term peripheral hypotension mainly 
because of venous pressure is also being decreased. The authors believe that this is one of 
the key mechanisms of action involved in the complex cardiovascular effects of zolmitrip-
tan. In addition to these mechanisms of the peripheral blood pressure regulation, there is 
also available evidence for the central regulation. For example, Watts et al. (3) describe that 
central serotoninergic effects on the blood pressure are due to the stimulation of serotonin 
receptors located in the wide intraneuronal network that defines both sympathetic and 
vagal regulation.
We could explain the tachycardia observed in male rats relying on the classical prin-
ciple of the baroreceptor reflex mechanism and the normal functions of the sinus node 
mediated by the afferent stimulation to the vasomotor center in the brain. Conversely, 
migraine could provoke some vagal effects with its cerebral ischemia that may result in a 
subsequent hypotension (9).
There are similar outcomes to our results, but perceived from three double-blinded, 
randomized, crossover studies with frovatriptan, rizatriptan, almotriptan and zolmitriptan 
led on hypertensive and normotensive patients (6). These outcomes claim that there was no 
increase or even decrease in the blood pressure during their trials, and no further changes 
in the antihypertensive therapy were applied. The heart rate (HR) was not changed, nor a 
higher incidence of adverse drugs’ reactions was observed in hypertensive patients. The 
only exception was that some of the treated subjects were less susceptible to triptan therapy, 
which, we believe, is important for the overall cardiovascular profile of these drugs.
Having in mind the pharmacokinetics of frovatriptan and its moderate affinity to 
5-HT7 receptor (pKi/IC50 = 6.7 nmol L–1), we suggest that this receptor and its influence are 
involved in some hemodynamic parameters (10). There is sufficient data proving that 
5-HT7 receptors (located in nucleus tractus solitarii) are involved in the central regulation of 
arterial pressure and the heart rate.
Expression of 5-HT7 receptors, apart from the CNS and peripheral nervous system, is 
also found in smooth muscle cells and blood vessels of the cardiovascular system, where 
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they mediate relaxation in arteries and veins (11). These are G-protein-coupled receptors 
(Gs) that increase the intracellular adenylate cyclase activity and cAMP levels (12). It is well 
known that the increase of cAMP and the following activation of protein kinase A (PKA) 
lead to sustained SM relaxation. This relaxation exactly supports our hypothesis about the 
decrease in DBP and MAP in female rats treated with frovatriptan 5 mg kg–1.
In the literature, there is data that frovatriptan and almotriptan possess a moderate 
affinity to the 5-HT1A receptor (13, 14). Having this mind, we may explain why male rats 
treated with frovatriptan in both dosages decrease all four hemodynamic parameters SBP, 
DBP, PP and MAP. According to Ramage (15), the central stimulation of 5-HT1A-receptors 
could reduce the vasoconstrictor sympathetic nerve activity and increase the cardiac vagal 
nerve activity, both leading to a decrease in blood pressure. This hypothesis is confirmed by 
van den Buuse and Wegener (16). In their experiment, they found a significant decrease in 
the blood pressure after applying intravenously 5-HT1A receptor agonist 8-OH-DPAT to rats.
On the other hand, Pagniez et al. (17) had previously established hypotension and 
bradycardia on anesthetized rats treated with sumatriptan and rizatriptan. Furthermore, 
the authors prove 5-HT1B/1D receptors to be poorly involved in these effects by co-adminis-
tration of GR127935, a potent and specific 5-HT1B/1D antagonist. They do not exclude the 
possibility for a secondary reduced sympathetic vascular tone.
The sympathetic varicosities of the nerves innervating small arteries and arterioles 
express 5-HT1B/1D receptors. Stimulation of these receptors results in the inhibition of NE 
release and the reduction of nerve-stimulated contraction. Thus, there are multiple ways 
in which 5-HT interacts with arteries, promoting both vasoconstriction and vasorelaxation 
(7). Based on this hypothesis, we could explain the fluctuations of the blood pressure in 
our results in frovatriptan and almotriptan treated male and female rats.
CONCLUSIONS
Our experiment was conducted with selective serotoninergic agonists frovatriptan 
and almotriptan. We had examined the effects on intact male and female rats and came to 
the conclusion that these effects were beneficial to the cardiovascular system of female 
rats. The receptors’ affinity of frovatriptan and almotriptan to the specific subtypes of 
5-HT receptors could explain some of the haemodynamic fluctuations.
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